Autoimunne haemolytic anaemia as a complication of a Chronic Lymphocytic Leukaemia

Abstract

Chronic Lymphocytic Leukaemia (CLL) is a lymphoproliferative disorder with a low malignancy whose essence is a clonal proliferation of malignant transformed B-lymphocytes, with impaired abilities while apoptotic destruction and uncontrolled proliferation. Their combination of subsequently experiencing is a gradual increase in the quantity of lymphocytes. This disease is associated with many infectious and autoimmune complications in the absence of a physiological response to antigenic stimulus. It is most often autoimmune haemolytic anaemia (AIHA) and autoimmune thrombocytopenia. The prognosis of the disease is heterogenous, disease treatment is comprehensive and includes both chemotherapy, chemoimunotherapy, so a bone marrow transplant. The effectiveness of treatment in the last years has increased significantly, particularly using new agents as inhibitor of tyrosine kinase ibrutinib, inhibitor of PI3K idelalisib, inhibitor of Syk, inhibitor of Bcl-2 and the other. The disease has a dynamic character and is still the subject of a series of studies, which may, in the future, improve the prognosis of affected patients. The following case report presents the progress of the disease patients with CLL, an elaborate creation of autoimmune haemolytic anaemia in the field many of co-morbidities.